Revanth Reddy Unveils Next-Gen Life Sciences Policy in Davos

The policy targets investments of $25 billion and the creation of nearly five lakh jobs, marking a decisive shift from scale-driven manufacturing to value-led, innovation-powered growth.

Announced in the presence of IT and industries minister D. Sridhar Babu, special chief secretary, IT and Industries, Sanjay Kumar and Telangana Life Sciences CEO Shakthi M. Nagappan, the policy seeks to strengthen Telangana’s role in global healthcare, advanced therapeutics and sustainable bio-manufacturing. It stresses high-value research and development, advanced biologics, next-generation therapies and environmentally responsible manufacturing, while reinforcing Hyderabad’s standing as a global innovation hub.

Revanth Reddy said Telangana was building one of the world’s most trusted bioscience ecosystems capable of delivering global health impact. He noted that unveiling the policy in Davos reflected the state’s confidence in cross-border collaboration, global capital and shared innovation agendas.

Recalling that investments worth ₹73,000 crore had been attracted in the last two years, he said the new policy aimed to draw nearly ₹2 lakh crore over the next five years.

The policy builds on Telangana’s strong manufacturing base while deepening its innovation capabilities. Hyderabad already hosts research, digital and global capability centres of leading global life sciences companies such as Amgen, Sanofi, Bristol Myers Squibb and Lilly, underlining confidence in the state’s scientific talent and infrastructure. A major reform is the recognition of R&D units as full-fledged industrial enterprises, enabling them to access incentives on par with manufacturing facilities.

Sridhar Babu said the policy prioritises frontier science and advanced platforms such as cell and gene therapies, peptides, precision fermentation and digital health. He added that the ecosystem would be strengthened across clinical research, diagnostics, pharma services, medical electronics and data-driven healthcare, making Telangana a preferred destination for global life sciences hubs.

Special CS Sanjay Kumar said the framework was designed to accelerate the adoption of emerging technologies including artificial intelligence and next-generation therapeutics, while nurturing a highly skilled workforce. Nagappan highlighted the establishment of a dedicated Life Sciences Innovation Fund, with an initial corpus of Rs. 100 crore and scalable up to ₹1,000 crore, to catalyse early- and growth-stage innovation, particularly in biotherapeutics.

A flagship initiative under the policy is the development of the Green Pharma City, a sustainable industrial cluster built on zero liquid discharge, energy efficiency and net-zero practices. Ten pharma villages along the Outer Ring Road are planned to promote decentralised and balanced growth. The expansion of Genome Valley, strengthening of the Medical Devices Park and creation of a Bio-Innovation and Bio-Manufacturing Cluster are also envisaged.

The policy proposes the 1Bio facility, a first-of-its-kind growth-phase centre and biopharma scale-up manufacturing hub in India, along with the Telangana School of Life Sciences to nurture future-ready talent. It also underscores Hyderabad’s global standing as home to the WEF’s Fourth Industrial Revolution Centre focused on healthcare and life sciences. Together, these measures aim to transform Telangana from a key manufacturing base into a global originator of advanced therapies and innovation platforms.